Adaptive Posture-Balance Cardiac Rehabilitation Exercise Significantly Improved Physical Tolerance in Patients with Cardiovascular Diseases

Cardiac rehabilitation (CR) requires more professional exercise modalities to improve the efficiency of treatment. Adaptive posture-balance cardiac rehabilitation exercise (APBCRE) is an emerging, balance-based therapy from clinical experience, but lacks evidence of validity. Our study aimed to observe and assess the rehabilitation effect of APBCRE on patients with cardiovascular diseases (CVDs). All participants received one-month APBCRE therapy evenly three times per week and two assessments before and after APBCRE. Each assessment included cardiopulmonary exercise testing (CPET), resting metabolic rate (RMR) detection, and three questionnaires about general health. The differences between two assessments were analyzed to evaluate the therapeutic effects of APBCRE. A total of 93 participants (80.65% male, 53.03 +/- 12.02 years) were included in the analysis. After one-month APBCRE, oxygen uptake (VO2, 11.16 +/- 2.91 to 12.85 +/- 3.17 mL/min/kg, p < 0.01) at anaerobic threshold (AT), ventilation (VE, 28.87 +/- 7.26 to 32.42 +/- 8.50 mL/min/kg, p < 0.01) at AT, respiratory exchange ratio (RER, 0.93 +/- 0.06 to 0.95 +/- 0.05, p < 0.01) at AT and oxygen uptake efficiency slope (OUES, 1426.75 +/- 346.30 to 1547.19 +/- 403.49, p < 0.01) significantly improved in CVD patients. The <= 55-year group had more positive improvements (VO2 at AT, 23% vs. 16%; OUES, 13% vs. 6%) compared with the >55-year group. Quality of life was also increased after APBCRE (47.78 +/- 16.74 to 59.27 +/- 17.77, p < 0.001). This study proved that APBCRE was a potentially available exercise rehabilitation modality for patients with CVDs, which performed significant increases in physical tolerance and quality of life, especially for <= 55-year patients.

Automated summary

Adaptive posture-balance cardiac rehabilitation exercise (APBCRE) has significant rehabilitation effects on patients with cardiovascular diseases (CVDs), improving physical tolerance and quality of life, especially for patients below the age of 55.